Altimmune, Inc. ALT

US Biotechnology

$1.95 ▼ -8.02% ($-0.17)

⬇️ Below Yest. Low 🔥 High Short Interest 📅 Earnings This Week

Open $2.13

Prev Close $2.12

Day Range $1.91 – $2.13

52W Range $1.91 – $6.44

Market Cap $412.38M

Beta 0.16

EPS (TTM) $-0.78

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2005-10-06
Shares Out.	194,520,000
Website	altimmune.com/ ↗
Phone	12406541450
Employees	57
Revenue	$0
Gross Profit	$0
Net Income	-$22.8M
Free Cash Flow	-$76.6M
Total Assets	$527.2M
Total Liabilities	$53.0M
Equity	$474.2M

About Altimmune, Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune, Inc. is a publicly traded company under the ticker symbol ALT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.